-
-
-
-
-
-
-
Protalix BioTherapeutics (PLX) Issues 2023 Letter to Stockholders
-
-
-
-
-
-
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Di
-
-
-
-
-
-
-
Protalix BioTherapeutics (PLX) Reports Complete Treatment Period for Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for Proposed Treatment of Fabry Disease
-
-
-
-
-
12,341 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All